Showing 1 to 12 of 14 results
Eli Lilly CEO Calls UK "Worst in Europe" for Drug Prices, Threatening Investment
Eli Lilly's CEO, Dave Ricks, criticized the UK's drug pricing regime as the "worst in Europe," citing it as a reason for the pharmaceutical industry's withdrawal of nearly £2 billion in planned investments.
Eli Lilly CEO Calls UK "Worst in Europe" for Drug Prices, Threatening Investment
Eli Lilly's CEO, Dave Ricks, criticized the UK's drug pricing regime as the "worst in Europe," citing it as a reason for the pharmaceutical industry's withdrawal of nearly £2 billion in planned investments.
Progress
56% Bias Score
Albanese-Chalmers Rift Threatens Australian Economic Reform
Treasurer Jim Chalmers's proposed economic reforms face resistance from Prime Minister Anthony Albanese, creating internal tension within the government and potentially hindering efforts to improve the Australian economy, according to Nationals senator Bridget McKenzie.
Albanese-Chalmers Rift Threatens Australian Economic Reform
Treasurer Jim Chalmers's proposed economic reforms face resistance from Prime Minister Anthony Albanese, creating internal tension within the government and potentially hindering efforts to improve the Australian economy, according to Nationals senator Bridget McKenzie.
Progress
36% Bias Score
Trump Demands US Drug Prices Match Lower Global Prices
President Trump is demanding that 17 major US pharmaceutical companies match their US drug prices to the much lower prices offered to patients in other countries within 60 days, threatening unspecified consequences if they don't comply, although experts say this is unlikely to happen.
Trump Demands US Drug Prices Match Lower Global Prices
President Trump is demanding that 17 major US pharmaceutical companies match their US drug prices to the much lower prices offered to patients in other countries within 60 days, threatening unspecified consequences if they don't comply, although experts say this is unlikely to happen.
Progress
48% Bias Score
Lawsuit Challenges AbbVie's Humira Pricing, Highlighting Drug Cost Debate
A Dutch foundation is suing AbbVie for excessive profits from Humira, arguing its high price displaced other healthcare needs; AbbVie counters that high prices are needed to cover development costs, and the patent expiry in 2018 caused prices to plummet by nearly 90% by 2023.
Lawsuit Challenges AbbVie's Humira Pricing, Highlighting Drug Cost Debate
A Dutch foundation is suing AbbVie for excessive profits from Humira, arguing its high price displaced other healthcare needs; AbbVie counters that high prices are needed to cover development costs, and the patent expiry in 2018 caused prices to plummet by nearly 90% by 2023.
Progress
60% Bias Score
Trump Administration Intensifies Pressure on Pharmaceutical Pricing
The Trump administration's intensified pressure on the pharmaceutical industry, including tariffs and price negotiation frameworks, aims to address high US healthcare spending (17.6% of GDP) by potentially aligning US drug prices with lower prices in other developed countries, but faces challenges i...
Trump Administration Intensifies Pressure on Pharmaceutical Pricing
The Trump administration's intensified pressure on the pharmaceutical industry, including tariffs and price negotiation frameworks, aims to address high US healthcare spending (17.6% of GDP) by potentially aligning US drug prices with lower prices in other developed countries, but faces challenges i...
Progress
44% Bias Score
Trump Executive Order Aims to Slash Prescription Drug Prices
President Trump signed an executive order on Monday mandating that drugmakers offer US patients the lowest price paid for a drug in a peer country, threatening consequences such as increased drug importation and FDA actions if manufacturers don't significantly lower prices; this broad measure extend...
Trump Executive Order Aims to Slash Prescription Drug Prices
President Trump signed an executive order on Monday mandating that drugmakers offer US patients the lowest price paid for a drug in a peer country, threatening consequences such as increased drug importation and FDA actions if manufacturers don't significantly lower prices; this broad measure extend...
Progress
48% Bias Score
Trump Demands Pharmaceutical Companies Lower Drug Prices
President Trump's 60-day ultimatum to 17 pharmaceutical companies demands proposals for lowering U.S. drug prices to match the lowest prices in developed nations, aiming to correct decades-long pricing imbalances and potentially reforming the entire healthcare ecosystem.
Trump Demands Pharmaceutical Companies Lower Drug Prices
President Trump's 60-day ultimatum to 17 pharmaceutical companies demands proposals for lowering U.S. drug prices to match the lowest prices in developed nations, aiming to correct decades-long pricing imbalances and potentially reforming the entire healthcare ecosystem.
Progress
44% Bias Score
Trump Demands US Drug Price Cuts from 17 Pharmaceutical Companies
President Trump sent letters to 17 pharmaceutical CEOs on Thursday, demanding a 60-day price reduction on drugs or facing unspecified consequences; this follows a May executive order reinstating a "nation most favored" plan to link US drug prices to lower international rates, and resulted in stock d...
Trump Demands US Drug Price Cuts from 17 Pharmaceutical Companies
President Trump sent letters to 17 pharmaceutical CEOs on Thursday, demanding a 60-day price reduction on drugs or facing unspecified consequences; this follows a May executive order reinstating a "nation most favored" plan to link US drug prices to lower international rates, and resulted in stock d...
Progress
52% Bias Score
PBMs: The Primary Driver of High Drug Prices
The FTC and DOJ listening sessions revealed that Pharmacy Benefit Managers (PBMs), not pharmaceutical companies, are the primary cause of high drug prices due to their anti-competitive practices; the three largest PBMs control 80% of prescriptions, favoring higher-priced drugs and limiting access to...
PBMs: The Primary Driver of High Drug Prices
The FTC and DOJ listening sessions revealed that Pharmacy Benefit Managers (PBMs), not pharmaceutical companies, are the primary cause of high drug prices due to their anti-competitive practices; the three largest PBMs control 80% of prescriptions, favoring higher-priced drugs and limiting access to...
Progress
56% Bias Score
Dutch Court to Rule on AbbVie's Humira Pricing Lawsuit
A Dutch court will rule on a lawsuit against AbbVie for allegedly making €1 billion in excessive profits from its rheumatoid arthritis drug Humira (adalimumab) between 2004 and 2018; the foundation Farma ter Verantwoording claims this money could have improved the health of 14,000 people.
Dutch Court to Rule on AbbVie's Humira Pricing Lawsuit
A Dutch court will rule on a lawsuit against AbbVie for allegedly making €1 billion in excessive profits from its rheumatoid arthritis drug Humira (adalimumab) between 2004 and 2018; the foundation Farma ter Verantwoording claims this money could have improved the health of 14,000 people.
Progress
52% Bias Score
Medicare Drug Pricing: Price Controls vs. Market Negotiation
The Inflation Reduction Act uses price controls rather than negotiation to set maximum drug prices, creating perverse incentives for government and private insurers that lead to under-provision of care for the sick. Future reforms should promote free-market principles.
Medicare Drug Pricing: Price Controls vs. Market Negotiation
The Inflation Reduction Act uses price controls rather than negotiation to set maximum drug prices, creating perverse incentives for government and private insurers that lead to under-provision of care for the sick. Future reforms should promote free-market principles.
Progress
56% Bias Score
Trump EO Seeks Systemic Solutions to High Prescription Drug Costs
President Trump's April 15th executive order directs officials to find solutions to high prescription drug prices by addressing misaligned incentives, PBM practices, and site-neutral payments within 180 days.
Trump EO Seeks Systemic Solutions to High Prescription Drug Costs
President Trump's April 15th executive order directs officials to find solutions to high prescription drug prices by addressing misaligned incentives, PBM practices, and site-neutral payments within 180 days.
Progress
44% Bias Score
Showing 1 to 12 of 14 results